Document is current
Any future updates will be listed below
-
Authors
Dong, Sharlene https://orcid.org/0000-0002-6983-6012
Banerjee, Rahul https://orcid.org/0000-0003-3781-5441
Khan, Adeel M. https://orcid.org/0000-0002-9462-6316
Wang, Mengru
Wang, Xiaoliang https://orcid.org/0000-0001-5184-2935
Afghahi, Anosheh
Afrough, Aimaz https://orcid.org/0000-0003-2645-8557
Janakiram, Murali
Wang, Bo
Cowan, Andrew J.
Sperling, Adam S. https://orcid.org/0000-0002-9369-4413
Anderson, Larry D. Jr https://orcid.org/0000-0002-6531-9595
Rajkumar, S. Vincent https://orcid.org/0000-0002-5862-1833
Kaur, Gurbakhash https://orcid.org/0000-0002-2510-6536
- License Information
-
More Information
Article History
Received: 1 August 2024
Revised: 16 January 2025
Accepted: 12 March 2025
First Online: 28 March 2025
Competing interests
: RB: Consulting: Adaptive, BMS, Caribou Biosciences, Genentech, Gilead/Kite, GSK, Janssen, Karyopharm, Legend Biotech, Pfizer, Poseida Therapeutics, Sanofi, SparkCures; Research: Abbvie, BMS, Janssen, Novartis, Pack Health, Prothena, Sanofi. AMK: Research: Sanofi, Janssen. XW: Employment: Flatiron Health, Inc. (independent subsidiary of the Roche Group), stock ownership, Roche. MW: Employment: Flatiron Health, Inc. (independent subsidiary of the Roche Group), stock ownership, Roche. AA: Employment: Flatiron Health, Inc. (independent subsidiary of the Roche Group), stock ownership, Roche. MJ: Consulting: Janssen, BMS, Legend. Research: Janssen, BMS, Fate Therapeutics. ASS: Consulting: Novartis. LDA Jr: Consulting: Janssen, Celgene, BMS, Amgen, GSK, AbbVie, Beigene, Cellectar, Sanofi, Prothena. Research: BMS, Celgene, GSK, Janssen, Abbvie. AJC: Consulting: BMS, Adaptive; Research: Adaptive Biotechnologies, Harpoon, Nektar, BMS, Janssen, Sanofi, AbbVie. GK: Consulting: BMS, Arcellx, Sanofi, Janssen, Cellectar, Pfizer, Kedrion; Research: BMS, Janssen, Abbvie. GK: Consulting: BMS, Arcellx, Sanofi, Janssen, Cellectar, Pfizer, Kedrion, Kite; Research: BMS, Janssen, Abbvie, Arcellx. The remaining authors have no disclosures to report.
: All methods were performed in accordance with the relevant guidelines and regulations. This retrospective study was reviewed and exempted by the University of Texas Southwestern Institutional Review Board without the need for individual patient consent. No patient-identifiable information was shared during analyses or are present in this manuscript.
